尽管第二季度的每股收益为-0.70美元,但Dyne Therapeutics公司获得了10位分析师的"买入"评级, Dyne Therapeutics receives "Buy" rating from 10 analysts with a $50.60 price target, despite reporting Q2 EPS of -$0.70.

以肌肉疾病为主的临床阶段生物技术公司Dyne治疗公司,从10名分析师获得平均“Buy”评分,12个月的价格目标是50.60美元。 Dyne Therapeutics, a clinical-stage biotechnology firm focused on muscle diseases, has received an average "Buy" rating from ten analysts, with a 12-month price target of $50.60. 该公司报告,每股Q2收入为-0.70美元,超过预期。 The company reported a Q2 earnings per share of -$0.70, surpassing expectations. 机构所有权高达96.68%,注意到大量投资活动。 Institutional ownership is high at 96.68%, with significant investment activity noted. 各种分析家最近对价格目标的提升反映了对公司前景的积极看法。 Recent upgrades in price targets from various analysts reflect positive sentiment about the company's prospects.